Baclofen formulations and methods of minimizing patient exposure to metabolite variations

US12383522B2 · kind B2 · utility

Assignee

• AMNEAL PHARMACEUTICALS LLC · US

Inventors

• Leonard O'Mahony · Mullingar, IE
• Sharon Hamm · Land O' Lakes, US
• John Devane · Dublin, IE
• David Penake · San Francisco, US
• Wolfgang Mohr · Freiburg (Elbe), DE
• Manuel Weinheimer · Neustadt an der Weinstraße, DE

Key dates

• Filing date: Nov 14, 2023
• Grant date: Aug 12, 2025
• Expiry date: Nov 14, 2043

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/197
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Baclofen formulations, including formulations that minimize variability between doses, that minimize variation in patient exposure to baclofen metabolites, and are bioequivalent in regards to baclofen versus M1 metabolite ratios of baclofen tablets.